Adocia SA (EPA:ADOC)

Market Cap	88.29M +37.1%
Revenue (ttm)	3.85M -68.3%
Net Income	-16.59M
EPS	n/a
Shares Out	19.59M
PE Ratio	n/a
Forward PE	18.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	556,833
Open	4.500
Previous Close	4.506
Day's Range	4.050 - 4.552
52-Week Range	3.300 - 12.400
Beta	0.27
Analysts	Strong Buy
Price Target	13.00 (+216.61%)
Earnings Date	Sep 24, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 80
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for ADOC stock is "Strong Buy." The 12-month stock price target is €13.00, which is an increase of 216.61% from the latest price.

Price Target

€13.00

(216.61% upside)

Analyst Consensus: Strong Buy